Latanoprost Stulln Sine 50 Mikrogramm/Ml Augentropfen, Lösung Im Einzeldosisbehältnis

Latanoprost, the active ingredient in Latanoprost Stulln Sine 50 µg/mL Augentropfen, Lösung Im Einzeldosisbehältnis, is a prostaglandin F2α analog presented as a 50 µg/mL ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Latanoprost Stulln Sine 50 µg/mL Augentropfen, Lösung Im Einzeldosisbehältnis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to manage conditions characterized by elevated intra‑ocular pressure. - Open-angle glaucoma: reduces intra‑ocular pressure, helping to prevent optic nerve damage. - Ocular hypertension: lowers eye pressure to reduce risk of progression to glaucoma. - Secondary open-angle glaucoma: provides pressure‑lowering effect similar to primary disease.

Latanoprost may cause ocular and systemic adverse reactions, most of which are mild and reversible. Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye irritation: transient burning or stinging. - Increased eyelash growth: longer, thicker lashes. Serious or Rare Side Effects: - Persistent ocular inflammation: uveitis or iritis. - Corneal edema: swelling of the cornea. - Severe allergic reaction: swelling, itching, or rash.

When prescribing Latanoprost, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown; caution advised. - Pre‑existing ocular inflammation: may exacerbate condition. - Concomitant ocular surgery: postpone use until healing is complete. - Contact lens wearers: may experience deposits; advise removal before instillation. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents, affecting efficacy or safety. Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may reduce Latanoprost’s pressure‑lowering effect. - Prostaglandin analogs (e.g., bimatoprost): concurrent use can increase risk of ocular side effects. Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive intra‑ocular pressure reduction; monitor pressure. - Systemic carbonic anhydrase inhibitors: potential enhanced hypotensive effect. - Anticholinergic agents: may affect tear production, increasing discomfort.